ILMN

Analysts Run the Apple Asylum — Tuesday’s IP Market Recap

Price targets keep climbing to the moon: $715, $910 -- even $1,001. More 

Why Illumina’s Future Remains Bright

Rejection of Roche's takeover bid has cooled ILMN shares, but many expect Roche to step up its advances. If not, Illumina still has great growth prospects. More 

Illumina Sparks Mean Gene Rally — Wednesday’s IP Market Recap

A hostile offer from Roche warms investors' hearts. More 

Roche’s Hostile Bid for Illumina Could Reach $60 Per Share

Swiss health care giant Roche made a hostile bid to buy Illumina for $44.50 per share, but many think that number will be higher when all is said and done. More 

5 Earnings Predictions That Will Impact Your Portfolio Now

These two companies look like they will release strong, estimate-beating results, but these three others may not fare as well. More 

Illumina Shares Take a Tumble

The biotech's stock hits the skids after the company warns revenue will take a hit. More